



VOLUME SIX HUNDRED AND TEN

# METHODS IN ENZYMOLGY

## Modern Approaches in Drug Discovery

Edited by

**CHARLES A. LESBURG**

*Department of Chemistry*

*Merck & Co.*

*Boston, MA, United States*



Mahidol University

Faculty of Science

Stang Mongkolsuk Library and Information Division



**ACADEMIC PRESS**

An imprint of Elsevier

# CONTENTS

<i>Contributors</i>	<i>ix</i>
<i>Preface</i>	<i>xiii</i>
<b>1. Risk Management in Early Discovery Medicinal Chemistry</b>	<b>1</b>
Gurpreet Singh, Jayme L. Dahlin, and Michael A. Walters	
1. Introduction	2
2. Risk in Drug Discovery	2
3. Management of Risks in Drug Discovery	2
4. General Strategies for Managing Risks	4
5. Our Four Pillars of Early Discovery Derisking	7
6. Advanced Topics	20
7. Summary	21
References	21
Further Reading	25
<b>2. Target Identification Using Chemical Probes</b>	<b>27</b>
Moses Moustakim, Suet Ling Felce, Nancy Zaarour, Gillian Farnie, Fiona E. McCann, and Paul E. Brennan	
1. Introduction	29
2. Target Engagement Assays	33
3. Probe Screening in Patient-Derived Assays	38
4. Case Studies	43
5. Summary and Outlook	52
References	52
<b>3. Mining the Microbiome for Drug Targets</b>	<b>59</b>
Qi Wang, Fangming Yang, and Huijue Jia	
1. Introduction	60
2. Sample Collection and Sequencing for MWAS	61
3. Identifying Potential Drug Targets	66
4. Summary and Outlook	70
References	70

<b>4. Screening Library Design</b>	<b>73</b>
Stephanie Kay Ashenden	
1. Diversity in Screening Library Design	74
2. Methods	80
3. Case Studies	82
4. Natural Products for Screening Library Design	84
5. Library Design for Screening Fragments	85
6. Virtual Library Design	86
7. Creating a Screening Library	87
8. Final Thoughts	91
References	92
<b>5. Design of a Fragment-Screening Library</b>	<b>97</b>
Ashley Taylor, Bradley C. Doak, and Martin J. Scanlon	
1. Introduction	97
2. Compiling a Dataset of Compounds	98
3. Calculating Properties and Selecting a Representative Set	102
4. Library Quality Control	105
5. Sample Storage and Preparation	106
6. 1D <sup>1</sup> H NMR	107
7. <sup>1</sup> H Water-LOGSY	109
8. Failure Rate	110
9. SPR Reference Surface Binding	110
10. Mixture Design	111
11. Conclusion	112
References	113
<b>6. Genetically Encoded Cyclic Peptide Libraries: From Hit to Lead and Beyond</b>	<b>117</b>
Jacob Valentine and Ali Tavassoli	
1. Introduction	118
2. SICLOPPS	119
3. mRNA Display	124
4. The Path From Peptide Hit to the Clinic	126
5. Conclusions	129
References	130
<b>7. A Guide to Run Affinity Screens Using Differential Scanning Fluorimetry and Surface Plasmon Resonance Assays</b>	<b>135</b>
Christian Bergsdorf and S. Kirk Wright	
1. Introduction	136
2. Protein Denaturation Assays in Hit Identification	138

---

3. SPR in Low Molecular Weight Compound Screening	149
4. Conclusion	160
Acknowledgments	162
References	162
<b>8. Second-Harmonic Generation (SHG) for Conformational Measurements: Assay Development, Optimization, and Screening</b>	<b>167</b>
Tracy A. Young, Ben Moree, Margaret T. Butko, Bason Clancy, Mary Geck Do, Tarun Gheyi, John Strelow, Juan J. Carrillo, and Joshua Salafsky	
1. Introduction	168
2. Technology Background	169
3. Assay Development	171
4. Running an SHG Assay	181
5. SHG Assay Development: Example	182
6. Screening	184
References	190
<b>9. An Array-Based Ligand Discovery Platform for Proteins With Short Half-Lives</b>	<b>191</b>
Becky S. Leifer, Shelby K. Doyle, André Richters, Helen L. Evans, and Angela N. Koehler	
1. Introduction	192
2. Expression of Protein by IVT	195
3. SMM Screening	203
4. Analysis of SMM Screening Data	208
5. Iterative Optimization of SMM Screening Conditions	212
6. Summary	214
Acknowledgments	215
References	215
<b>10. High Content, Phenotypic Assays and Screens for Compounds Modulating Cellular Processes in Primary Neurons</b>	<b>219</b>
Miklos Kepiro, Boglarka H. Varkuti, and Ronald L. Davis	
1. Introduction	220
2. HCS for Compounds Increasing Mitochondrial Content, Elongation, and Improving Health	222
3. Summary and Conclusions	247
References	247
Further Reading	250

---

<b>11. Achieving a Good Crystal System for Crystallographic X-Ray Fragment Screening</b>	<b>251</b>
Patrick M. Collins, Alice Doungamath, Romain Talon, Alexandre Dias, Jose Brandao-Neto, Tobias Krojer, and Frank von Delft	
1. Introduction	252
2. Process Overview and Constraints on Crystals	253
3. Ways to Establish a Suitable Crystal System	255
4. Common Problems	258
5. Map and Model Considerations	261
6. Conclusion	262
References	263
<b>12. Hit-to-Lead: Hit Validation and Assessment</b>	<b>265</b>
Kirk E. Hevener, Russell Pesavento, JinHong Ren, Hyun Lee, Kiira Ratia, and Michael E. Johnson	
1. Introduction	266
2. Hit Assessment and Prioritization	266
3. Structure-Based Strategies	278
4. NMR Spectroscopy in Hit Screening/Validation	285
5. Hit-to-Lead: Assessment, Prioritization, and Improvement of Drug-Like Properties	290
6. Conclusions	299
References	300
<b>13. Knowledge-Based Approaches to Off-Target Screening</b>	<b>311</b>
Daniel R. McMasters	
1. Introduction	311
2. Classes of Off-Target Proteins	314
3. Knowledge-Based Approaches to Off-Target Screening	315
References	322